Individualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI

Mina Wageh Mohareb60 enrolled

Overview

Background:Diabetes and smoking are common factors found to increase platelet reactivity in patients undergoing primary PCI. Objective: Compare the individualized and combined effects of smoking and diabetes on the antiplatelet activity in patients undergoing primary PCI. Methods: sixty patients were recruited in this study. Patients were allocated to one of four groups according to the diabetes and smoking status. Non smokers- non diabetic patients, smokers non diabetic patients, non smokers diabetic patients, and smokers diabetic patients, 15 patients in each group. All patients received 180 mg ticagrelor before PCI. Platelet reactivity index(PRI) and maximum platelet aggregation were measured 24 hours after ticagrelor loading dose for each patient as indicators for antiplatelet efficacy. PRI and/or MPA values \> 50% were defined as high platelet reactivity.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Individualized and Combined Effects of Smoking and Diabetes on the Antiplatelet Activity in Patients Undergoing Primary Percutaneous Coronary Intervention

Interventions

Patients with acute coronary syndromes undergo primary PCI and administered 180 mg loading dose ticagrelor before PCI

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Acute coronary syndrome (ACS) undergoing PCI Exclusion Criteria: Patients who had a history of severe bleeding, serious bleeding tendency, history of intracranial hemorrhage, signs of active bleeding, thrombocytopenia, uncontrolled hypertension, hypersensitivity to the used drugs (clopidogrel or ticagrelor), concomitant use of strong CYP inducers or inhibitors, and/or severe liver disorders were excluded from the study. Patients with previous history of coronary artery disease, previous PCI or patients administering other antiplatelets were excluded from the current study.

Locations (1)

Faculty of medicine of girls, Cardiology department, Al-Azhar University in Cairo

Cairo, Egypt

RECRUITING

Outcomes

Primary Outcomes

Platelet Reactivity Index and maximum platelet aggregation

Platelet aggregation indicator

Time frame: 24 hours after PCI

Central Contacts

Nasima M El-Kenany, Ph.D

CONTACT

01007844927 mina.moharebmedicinewolters@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.